Business
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Late Breaking Posters Will Feature Data From Phase 2 LiFT Study Investigating LPCN 1144 in NASH SALT LAKE CITY, Nov. 1, 2021 /PRNewswire/ -- Lipocine Inc.
About this update from Lipocine Inc.
[{"type":"text","content":"Late Breaking Posters Will Feature Data From Phase 2 LiFT Study Investigating LPCN 1144 in NASH\n\n\nSALT LAKE CITY, Nov. 1, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that three abstracts have been selected for poster presentations during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) to take place November 12-15, 2021.\n\n \n \n \n \n \n \n\n \nPresentation Details:\nSession Title: \nLate-Breaking Abstract Posters\nPublication Number: \nLP46\nPoster Title: \n\"LPCN 1144 Therapy Demonstrates Histologic Benefits In The Phase 2 LiFT Study in Non-Alcoholic Steatohepatitis (NASH) Subjects\"\nSession Title: \nLate-Breaking Abstract Posters\nPublication Number: \nLP47\nPoster Title: \n\"Safety And Tolerability Of LPCN 1144 Treatment In Biopsy Confirmed NASH Subjects In The Phase 2 LiFT Study\"\nSession Title: \nNAFLD and NASH: Experimental: Clinical\nPublication Number: \n1876\nPoster Title: \n\"LPCN 1144 Improves Body Composition In Biopsy-Confirmed NASH Patients\"\nThe abstracts will be available for viewing by attendees of The Liver Meeting® 2021 on the AASLD website and the online planner of The Liver Meeting® app November 1, 2021 at 10:00 am ET and will be published in the December issue of HEPATOLOGY.\nAbout LipocineLipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice dail...